



## **JAGSONPAL PHARMACEUTICALS LIMITED**

Regd. Office. T-210 J, Shahpur Jat, New Delhi - 110 049 (INDIA)  
Fax 0091-11-26498341, 26494708, Phone: 0091-11-46181100, 46109900  
Email: [cs@jagsonpal.com](mailto:cs@jagsonpal.com); [nandita.singh@jagsonpal.com](mailto:nandita.singh@jagsonpal.com)  
CIN No. L74899DL1978PLC009181

Date: May 25<sup>th</sup>, 2021

The Manager Listing Agreement The National Stock Exchange of India Ltd. Exchange Plaza, Bandra-Kurla Complex Bandra (E), Mumbai - 400 051.	The Manager Listing Agreement The BSE Limited Pherojbhoy Jeejeebhoy Tower Dalal Street, Mumbai - 400 001.
<b>CM Quote: JAGSNPHARM</b>	<b>SCRIP Code: 507789</b>
<b>Subject: Outcome of the Meeting of Board of Directors of Jagsonpal Pharmaceuticals Limited Held on May 25<sup>TH</sup>, 2021</b>	

Dear Sir,

We wish to inform you that the Board of Directors of the Company at their meeting held today, (i.e., Tuesday, the 25<sup>th</sup> Day of May, 2021), have inter alia, approved to invest the funds of the company in its Associate Companies and in any other Body Corporate as and when required for the financial year 2021-22 (i.e., till the closure of the financial year ending on 31<sup>st</sup> March, 2022), subject to the limit as prescribed in Companies Act, 2013 read with rules made thereunder, SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 and other applicable laws and provision thereof.

The meeting was started at 1200 Hours and concluded at 1620 hours.

Kindly note the same and acknowledge the receipt.

For **JAGSONPAL PHARMACEUTICALS LIMITED**

**Nandita Singh**  
**Company Secretary & Compliance Officer**

**Membership No.: A48520**